• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Tumor markers"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-20 of 26

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      Angiogenesis in cancer of unknown primary: Clinicopathological study of CD34, VEGF and TSP-1 

      Karavasilis, V.; Malamou-Mitsi, Vassiliki D.; Briassoulis, E. Ch; Tsanou, E.; Kitsou, E.; Kalofonos, H. P.; Fountzilas, George; Fotsis, T.; Pavlidis, Nicholas (2005)
      Background: Cancer of unknown primary remains a mallignancy of elusive biology and grim prognosis that lacks effective therapeutic options. We investigated angiogenesis in cancer of unknown primary to expand our knowledge ...

    • Article  

      Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: Interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes 

      Pentheroudakis, George; Kotoula, V.; Roock, W. De; Kouvatseas, G.; Papakostas, P.; Makatsoris, T.; Papamichael, D.; Xanthakis, I.; Sgouros, J.; Televantou, D.; Kafiri, G.; Tsamandas, A. C.; Razi, E. D.; Galani, E.; Bafaloukos, Dimitrios; Efstratiou, I.; Bompolaki, I.; Pectasides, Dimitrios; Pavlidis, Nicholas; Tejpar, S.; Fountzilas, George (2013)
      Background: More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR monoclonal antibodies. We studied EGFR-axis messenger RNA (mRNA) expression and RAS, RAF, PIK3CA mutations in order ...

    • Article  

      Cancer of unknown primary site: 20 questions to be answered 

      Pavlidis, Nicholas; Pentheroudakis, George (2010)
      Cancer of unknown primary (CUP) is a common, well-recognized and heterogeneous clinical syndrome. Patients with CUP present with metastatic disease in the absence of an identifiable primary tumour despite a diagnostic ...

    • Article  

      Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study 

      Briassoulis, E. Ch; Kalofonos, H. P.; Bafaloukos, Dimitrios; Samantas, E.; Fountzilas, George; Xiros, N.; Skarlos, Dimosthenis V.; Christodoulou, C.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2000)
      Purpose: To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP). Patients and Methods: Seventy-seven consecutive CUP patients (45 women and 32 men; median ...

    • Article  

      Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective? 

      Pentheroudakis, George; Briassoulis, E. Ch; Karavasilis, V.; Fountzilas, George; Xeros, N.; Samelis, G.; Samantas, E.; Pavlidis, Nicholas (2005)
      Carcinoma of unknown primary (CUP) is characterized by dismal patient survival. The outcome of patients with two favourable risk CUP subsets was studied. Eighty patients diagnosed with either midline lymph node metastases ...

    • Article  

      Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients 

      Pectasides, Dimitrios; Pavlidis, Nicholas; Gogou, L.; Antoniou, F.; Nikolaides, C.; Tsikalakis, D.; Fountzilas, George (1996)
      A total of 209 postsurgical breast cancer patients were prospectively monitored with simultaneous serum level estimations of CA 15-3, mucin-like carcinoma-associated antigen (MCA), tumor polypeptide antigen (TPA), and ...

    • Article  

      Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors 

      Zagorianakou, N.; Stefanou, D. G.; Makrydimas, G.; Zagorianakou, P.; Briassoulis, E. Ch; Karavasilis, V.; Pavlidis, Nicholas; Agnantis, Niki J. (2006)
      Metallothioneins (MTs) are a family of cystein-rich metal-binding proteins, which are expressed in normal cells during fetal and postnatal life but also in a variety of human neoplasms. MT expression in human tumors has ...

    • Article  

      Endometrioid Carcinoma of the Prostate. The Diagnostic Value of Leu7 and Prostatic Specific Antigen 

      Stavropoulos, N. E.; Ioachim, E.; Sidoni, K.; Stefanou, D. G.; Klouvas, G. D.; Pavlidis, Nicholas (1993)
      Summary— In a case of endometrioid carcinoma of the prostate the expression of Leu7 and prostatic specific antigen (PSA) was studied immunohistochemically on paraffin sections. The same markers were studied in 14 cases of ...

    • Article  

      ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP) 

      Briassoulis, E. Ch; Ch, F. Tolis; Pavlidis, Nicholas (2001)

    • Article  

      Evaluation of six tumor markers in patients with carcinoma of unknown primary 

      Pavlidis, Nicholas; Kalef-Ezra, J. A.; Briassoulis, E. Ch; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Saferiadis, K.; Bairaktari, Eleni Th; Bafaloukos, Dimitrios; Maravegias, A.; Theoharis, D.; Fountzilas, George (1994)
      We have retrospectively evaluated six serum tumor markers in 85 patients with carcinoma of unknown primary. The serum levels of carcinoembryonic antigen (CEA), CA 19‐9, CA 15‐3, CA 125, β‐chorionic gonadotropin (β‐HCG) and ...

    • Article  

      Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials 

      Fountzilas, George; Dafni, U.; Bobos, M.; Kotoula, V.; Batistatou, Anna; Xanthakis, I.; Papadimitriou, C.; Kostopoulos, I.; Koletsa, T.; Tsolaki, E.; Televantou, D.; Timotheadou, E.; Koutras, A. K.; Klouvas, G. D.; Samantas, E.; Pisanidis, N.; Karanikiotis, C.; Sfakianaki, I.; Pavlidis, Nicholas; Gogas, H.; Linardou, H.; Kalogeras, K. T.; Pectasides, Dimitrios; Dimopoulos, M. A. (2013)
      Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has ...

    • Article  

      Exploring the biology of cancer of unknown primary: Breakthroughs and drawbacks 

      Kamposioras, K.; Pentheroudakis, George; Pavlidis, Nicholas (2013)
      Background: Cancer of unknown primary (CUP) ranks among the ten most common malignancies worldwide. Cancer of unknown primary presents as disseminated disease, has a dismal prognosis and remains a diagnosis of exclusion. ...

    • Article  

      Five tumor markers in lung cancer: Significance of total and>-Bound sialic acid 

      Kakari, S.; Stringou, E.; Toumbis, M.; Ferderigos, A. S.; Poulaki, E.; Chondros, K.; Dema, A.; Kotsovoulou, V.; Pavlidis, Nicholas (1991)
      Total sialic acid (TSA) and > sialic acid (LSA) were evaluated in comparison to carcinoembryonic antigen (CEA) and ferritin and neuron specific enolase (NSE) in 152 untreated patients with primary lung cancer, 107 benign ...

    • Article  

      G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting 

      Briassoulis, E. Ch; Andreopoulou, E.; Ch, F. Tolis; Bairaktari, Eleni Th; Katsaraki, A.; Dimopoulos, M. A.; Fountzilas, George; Seferiadis, C.; Pavlidis, Nicholas (2001)
      BACKGROUND. Cancer antigen 15-3 (CA 15-3), a circulating marker that determines secreted products of the polymorphic MUC1 gene, has been established as a convenient tool for monitoring breast carcinoma patients. METHODS. ...

    • Article  

      Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: A quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial 

      Pentheroudakis, George; Kalogeras, K. T.; Wirtz, R. M.; Grimani, I.; Zografos, G.; Gogas, H.; Stropp, U.; Pectasides, Dimitrios; Skarlos, Dimosthenis V.; Hennig, G.; Samantas, E.; Bafaloukos, Dimitrios; Papakostas, P.; Kalofonos, H. P.; Pavlidis, Nicholas; Fountzilas, George (2009)
      Background Estrogen receptor (ER) and progesterone receptor (PgR) protein expression carry weak prognostic and moderate predictive utility for the outcome of early breast cancer patients on adjuvant chemohormonotherapy. ...

    • Article  

      Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors 

      Pentheroudakis, George; Spector, Y.; Krikelis, D.; Kotoula, V.; Meiri, E.; Malamou-Mitsi, Vassiliki D.; Fountzilas, George; Sanden, M.; Pavlidis, Nicholas; Benjamin, H.; Aharonov, R. (2013)
      No data exist on biologic differences between Cancer of unknown primary (CUP) and metastatic solid tumors of known primary site. We assigned a primary tissue of origin in 40 favorable CUP patients (A: serous peritoneal ...

    • Article  

      Matrix metalloproteinases in carcinoma of unknown primary 

      Karavasilis, V.; Malamou-Mitsi, Vassiliki D.; Briassoulis, E. Ch; Tsanou, E.; Kitsou, E.; Kalofonos, H. P.; Fountzilas, George; Fotsis, T.; Pavlidis, Nicholas (2005)
      BACKGROUND. The purpose was to study proteolysis-related molecules, matrix metalloproteinase-2 (MMP-2) and MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1), in carcinoma of unknown primary (CUP). METHODS. ...

    • Article  

      The neutrophil, not the tumor: Serum CA 15-3 elevation as a result of granulocyte-colony-stimulating factor-induced neutrophil MUC1 overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy 

      Pentheroudakis, George; Malamou-Mitsi, Vassiliki D.; Briassoulis, E. Ch; Damala, K.; Vassou, A.; Vartholomatos, G.; Kolaitis, N.; Pavlidis, Nicholas (2004)
      BACKGROUND. Patients with resected breast carcinoma who received granulocyte-colony-stimulating factor (G-CSF)-supported adjuvant chemotherapy exhibited an increase in their serum CA 15-3 levels. The authors investigated ...

    • Article  

      Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG) 

      Pentheroudakis, George; Kotoula, V.; Eleftheraki, A. G.; Tsolaki, E.; Wirtz, R. M.; Kalogeras, K. T.; Batistatou, Anna; Bobos, M.; Dimopoulos, M. A.; Timotheadou, E.; Gogas, H.; Christodoulou, C.; Papadopoulou, K.; Efstratiou, I.; Scopa, C. D.; Papaspirou, I.; Vlachodimitropoulos, D.; Linardou, H.; Samantas, E.; Pectasides, Dimitrios; Pavlidis, Nicholas; Fountzilas, George (2013)
      Background:Discrepant data have been published on the incidence and prognostic significance of ESR1 gene amplification in early breast cancer.Patients and Methods:Formalin-fixed paraffin-embedded tumor blocks were collected ...

    • Article  

      A retrospective analysis of serum CA 15-3 concentrations in patients with localised or metastatic renal cancer and its impact on prognosis and follow-up. A single-centre experience 

      Briassoulis, E. Ch; Pentheroudakis, George; Letsa, I.; Pavlidis, Nicholas (2002)
      Background. Monitoring patients with renal cancer for recurrence or progression is ineffective, inconvenient and costly. We conducted a retrospective analysis of serum CA 15-3 concentrations in a single-centre patient ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD